(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets

Colitis, Ulcerative Clinical Trial

Official title:

Multicenter, Open-Label Efficacy and Safety Study of Oral Budesonide-MMX 9mg Extended Release Tablets in Patients With Mild to Moderate, Active Ulcerative Colitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01100112
• Other study ID #: CB-01-02/06
• Status: Completed
• Phase: Phase 3
• Start date: February 2010
• Est. completion date: August 2010

Study information

• Verified date: November 2019
• Source: Bausch Health Americas, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open-label, 8 week study, to assess the efficacy and safety of oral Budesonide-MMX 9 mg Extended-release Tablets in patients with mild to moderate, active ulcerative colitis who are not in remission based on the Ulcerative Colitis Disease Activity Index in study CB-01-02/01 (parent study [NCT00679432]).

Description:

Patients who complete the parent study and who do not achieve clinical remission will be eligible to receive 8 weeks of open-label treatment with Budesonide-MMX 9mg if they satisfy the entry criteria for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 61
• Est. completion date: August 2010
• Est. primary completion date: July 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male and female patients 18 to 74 years of age, who are able to understand and voluntarily provide written informed consent

• Completed all Final Visit assessments for study CB-01-02/01 (NCT00679432) and are not in clinical remission

• Diagnosis of ulcerative colitis of mild to moderate severity with an Ulcerative Colitis Disease Activity Index (UCDAI) <or= 10 according to Sutherland

• Females of child-bearing potential must have had a serum pregnancy test performed at the Final Visit of the parent study, and must use an acceptable contraceptive method throughout the treatment period. Female subjects must also not be actively breast-feeding through the entire study period.

• Ability to comprehend the full nature and purpose of the study, including possible risks and side effects

• Ability to co-operate with the investigator and to comply with the requirements of the entire study

Exclusion Criteria:

• Did not complete study CB-01-02/01

• Achieved clinical remission in study CB-01-02/01

• Patients with severe ulcerative colitis (UCDAI >10)

• Patients with infectious colitis

• Evidence or history of toxic megacolon

• Severe anemia, leucopenia, or granulocytopenia

• Use of immunosuppressive agents in the last 8 weeks before the study

• use of anti-tumor necrosis factor alpha agents in the last three months

• Concomitant use of any rectal preparation for the treatment of ulcerative colitis

• Concomitant use of antibiotics

• Concurrent use of cytochrome P-450 3A4 (CYP3A4) inducers and CYP3A4 inhibitors.

• Patients with verified, presumed of expected pregnancy or ongoing lactation

• Patients with liver cirrhosis, or evident hepatic or renal disease or insufficiency and/or severe impairment of the bio-humoral parameters (i.e., 2x upper limit of normal for alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, or creatinine)

• Patients with severe disease(s) in other organs of systems

• Patients with local of systemic complications of other pathological states requiring a therapy with corticosteroids and/or immunosuppressive agents

• Patients diagnosed with Type 1 diabetes

• Patients diagnosed with or with a family history of glaucoma

• Patients with known hepatitis B, hepatitis C, or with human immunodeficiency virus (HIV), according to the local privacy policy

• Any other medical condition that in the principal investigator's opinion would make the administration of the study drug or study procedures hazardous to the subject or obscure the interpretation of adverse events

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer

Intervention

Drug:
• Budesonide
One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.

Locations

Country	Name	City	State
India	Santarus Clinical Investigational Site 9001	Andhra Pradesh
India	Santarus Clinical Investigational Site 9009	Andhra Pradesh
India	Santarus Clinical Investigational Site 9012	Andhra Pradesh
India	Santarus Clinical Investigational Site 9016	Andhra Pradesh
India	Santarus Clinical Investigational Site 9006	Assam
India	Santarus Clinical Investigational Site 9007	Gujarat
India	Santarus Clinical Investigational Site 9004	Karnataka
India	Santarus Clinical Investigational Site 9015	Karnataka
India	Santarus Clinical Investigational Site 9003	Kerala
India	Santarus Clinical Investigational Site 9002	Maharashtra
India	Santarus Clinical Investigational Site 9008	Maharashtra
India	Santarus Clinical Investigational Site 9013	Maharashtra
India	Santarus Clinical Investigational Site 9018	Rajasthan
India	Santarus Clinical Investigational Site 9005	Tamil Nadu
India	Santarus Clinical Investigational Site 9014	Uttar Pradesh

Sponsors (2)

Lead Sponsor	Collaborator
Bausch Health Americas, Inc.	Cosmo Technologies Ltd

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Percentage of Patients Achieving Clinical Remission	The primary efficacy endpoint is clinical remission at 8 weeks, defined as a Ulcerative Colitis Disease Activity Index score of < or = 1 with a score of 0 for both rectal bleeding and stool frequency, and > or = 1 point reduction from baseline in endoscopy score, without any sign of mucosal friability (a score of 0 for mucosal appearance).; The UCDAI has 4 components. Each component is scored on scale of 0 to 3 (total maximum [worst] score = 12). Definitions of component scores are as follows: stool frequency: 0 = normal frequency, 1 = 1 - 2 stools per day greater than normal frequency, 2 = 3 - 4 stools per day greater than normal frequency, and 3 = > 4 stools per day greater than normal frequency; rectal bleeding: 0 = none, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood; physician's rating of disease activity: 0 = normal, 1 = mild, 2 = moderate, 3 = severe; mucosal appearance: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.	At the end of the 8 week treatment period
Secondary	The Secondary Efficacy Endpoint is Clinical Improvement	The secondary efficacy endpoint is clinical improvement, defined as a drop in the Ulcerative Colitis Disease Activity Index score of > or = 3 points from baseline.	After 8 weeks treatment period
Secondary	Safety Evaluations: the Numbers of Patients Who Experience Serious Adverse Events (SAEs) or Other Nonserious Adverse Events (AEs) During the Course of the Study.	Safety will be assessed by evaluating SAEs and AEs. The outcome measure data are the numbers of patients who experienced SAEs or other nonserious AEs.	Throughout the 8 week treatment period
Secondary	Endoscopic Improvement	Greater or equal to a 1 point improvement in the mucosal appearance subscore of the ulcerative colitis disease activity index (UCDAI), from baseline to week 8.; The UCDAI mucosal appearance subscore is graded as follows: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.	8 weeks